BVI Introduces Serenity and Serenity Toric IOLs
BVI has introduced the Serenity and Serenity Toric premium monofocal IOLs, which it plans to launch in Europe at the upcoming ESCRS congress in Barcelona.
These non-diffractive, aspheric IOLs represent the second generation of BVI’s Isopure family, launched in 2019. Utilizing patented 'Isofocus' optic technology, these lenses are designed to offer a balance between Depth of Focus (DoF) and image quality, providing patients with far vision comparable to a monofocal lens, along with enhanced intermediate vision up to 66 cm.[1]
According to BVI, the new Serenity series continues the legacy of the Isopure series by maintaining the simplicity and reliability of a monofocal IOL while integrating Isofocal technology, which allows for spherical aberration correction across the entire optic diameter and customizes the level of spherical aberration based on dioptric power, resulting in superior visual outcomes.
The Serenity Toric IOL, designed for patients with astigmatism, benefits from BVI’s exclusive double C-loop POD platform. This platform provides exceptional maneuverability, enabling the lens to be rotated both clockwise and counterclockwise to precisely align the cylinder with the axis, BVI stated. This feature ensures that the toric IOL remains stable in the capsular bag,[2] with outcomes accurately predicted by BVI’s toric calculator.
Mr. Sheraz Daya MD FACP FACS FRCS(Ed) FRCOphth, a leading ophthalmic surgeon from the Centre For Sight in the UK, was among the first to implant the SERENITY IOL. He commented,
“It is wonderful to see this increased range of focus lens (IROF) on the same platform as the Finevision with 4 C loop haptics. I look forward to the Toric version as well, which I know will be Serenity stable with no rotation," said Sheraz Daya MD FACP FACS FRCS(Ed) FRCOphth, from the Centre For Sight in the UK, who was among the first to implant the Serenity IOL.
“We view this IOL as potentially a game-changer in the standard of care for monofocal procedures," Shervin Korangy, President and CEO of BVI, said in a company news release. "Our portfolio includes a wide range of IOLs, meticulously designed from material to haptics to optics, to provide the optimal outcome without the burden of retrofitting legacy predicate devices.”
The Serenity and Serenity Toric IOLs are slated for full commercial availability in CE-accepting markets by 2025. These lenses are not yet available for sale in the United States.
References
1. Bernabeu-Arias G, Beckers S, RincónRosales JL, Tañá-Rivero P, Bilbao-Calabuig R. Visual Performance at Different Distances After Implantation of an Isofocal Optic Design Intraocular Lens. J Refract Surg. 2023 Mar;39(3):150-157.
2. Robert Edward T Ang, Pedro Tañá-Rivero, Francisco Pastor-Pascual, Pavel Stodulka, Manfred Tetz, Isaak Fischinger. Visual and Refractive Outcomes After Bilateral Implantation of a Biconvex Aspheric Toric Monofocal Intraocular with a Double C-Loop Haptic Design. Clinical Ophthalmology 2023:17 2765–2776.